Effect of preinductin of metallothionein synthesis on clastogenicity of anticancer drugs in mice

Mutation Research Letters Pub Date : 1995-09-01 Epub Date: 2003-02-05 DOI:10.1016/0165-7992(95)90019-5

Ippei Nakagaw , Emiko Nishi , Akira Naganuma , Nobumasa Imura

{"title":"Effect of preinductin of metallothionein synthesis on clastogenicity of anticancer drugs in mice","authors":"Ippei Nakagaw , Emiko Nishi , Akira Naganuma , Nobumasa Imura","doi":"10.1016/0165-7992(95)90019-5","DOIUrl":null,"url":null,"abstract":"<div><p>The effect of pretreatment with metallothionein (MT) inducers (bismuth nitrate or zinc chloride) on clastogenicity of anticancer drugs was investigated. Bismuth nitrate (50 μmol/kg) or zinc chloride (400 μmol/kg) was administered s.c. to mice once a day for two days prior to treatment with 3.3 μmol/kg of <em>cis</em>-diamminedichloroplatinum(II) (<em>cis</em>-DDP), 3.4 μmol/kg of adriamycin (ADR), 72 μmol/kg of cyclophosphamide (CPA) or 0.41 μmol/kg of L-phenylalanine mustard (L-PAM). The frequency of occurrence of erythrocytes with micronuclei in bone marrow was increased by each anticancer drug at 24 h after treatment. Micronucleus formation was significantly prevented by pretreatment with either bismuth nitrate or zinc chloride. MT concentration in bone marrow cells of mice at the time of treatment with anticancer drugs increased to 2- and 3.5-fold by pretreatment with bismuth nitrate and zinc chloride, respectively. These results indicate that MT induction in bone marrow cells effectively prevents micronucleus induction of anticancer drugs.</p></div>","PeriodicalId":100934,"journal":{"name":"Mutation Research Letters","volume":"348 1","pages":"Pages 37-43"},"PeriodicalIF":0.0000,"publicationDate":"1995-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0165-7992(95)90019-5","citationCount":"26","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mutation Research Letters","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0165799295900195","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2003/2/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 26

Abstract

The effect of pretreatment with metallothionein (MT) inducers (bismuth nitrate or zinc chloride) on clastogenicity of anticancer drugs was investigated. Bismuth nitrate (50 μmol/kg) or zinc chloride (400 μmol/kg) was administered s.c. to mice once a day for two days prior to treatment with 3.3 μmol/kg of cis-diamminedichloroplatinum(II) (cis-DDP), 3.4 μmol/kg of adriamycin (ADR), 72 μmol/kg of cyclophosphamide (CPA) or 0.41 μmol/kg of L-phenylalanine mustard (L-PAM). The frequency of occurrence of erythrocytes with micronuclei in bone marrow was increased by each anticancer drug at 24 h after treatment. Micronucleus formation was significantly prevented by pretreatment with either bismuth nitrate or zinc chloride. MT concentration in bone marrow cells of mice at the time of treatment with anticancer drugs increased to 2- and 3.5-fold by pretreatment with bismuth nitrate and zinc chloride, respectively. These results indicate that MT induction in bone marrow cells effectively prevents micronucleus induction of anticancer drugs.

查看原文本刊更多论文

金属硫蛋白合成前体对小鼠抗癌药物断裂原性的影响

研究了金属硫蛋白（MT）诱导剂（硝酸铋或氯化锌）预处理对抗癌药物断裂原性的影响。在用3.3μmol/kg顺式二胺二氯铂（II）（顺式DDP）、3.4μmol/kg阿霉素（ADR）、72μmol/kg环磷酰胺（CPA）或0.41μmol/kg L-苯丙氨酸芥末（L-PAM）治疗前，小鼠每天皮下注射硝酸铋（50μmol/kg）或氯化锌（400μmol/kg。在治疗后24小时，每种抗癌药物都增加了骨髓中红细胞微核的发生频率。用硝酸铋或氯化锌预处理可显著防止微核的形成。在用抗癌药物治疗时，通过用硝酸铋和氯化锌预处理，小鼠骨髓细胞中的MT浓度分别增加到2倍和3.5倍。这些结果表明，骨髓细胞中的MT诱导有效地阻止了抗癌药物的微核诱导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mutation Research Letters

自引率

0.00%

发文量